As I mentioned above, there is not a ton of research on nolvadex and body fat. I posted one of the studies above and I think the one Macro was probably alluding to is this one:
Appl Radiat Isot 1998 May-Jun;49(5-6):643-5
Body composition measurements using DXA and other techniques in tamoxifen-treated patients.
Ali PA, al-Ghorabie FH, Evans CJ, el-Sharkawi AM, Hancock DA.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9569566&dopt=Abstract
The conclusion of that study was:
"...this retrospective study indicates that tamoxifen may lead to increase in fat content in women who are subjected to this treatment. We conclude that this observation is probably related to the agonistic oestrogenic effect of Tamoxifen on body fat. To our knowledge this deleterious effect has not been reported before and it should be taken into consideration when comprising different types of anti-oestrogenic drugs. Furthermore, patients should be warned about this side-effect when they are prescribed Tamoxifen therapy."
Considering the potential for hyperlipidemia, the reduction in circulating IGF-1 levels, and the increase in body fat, it might not be the best strategy for fat loss.
All this is said with the proviso that this research was carried out in women, the women were probably taking the nolvadex longer than you intend to, and the research was retrospective. The latter is important because it means the conditions under which the women took the nolvadex were not controlled. There were no comparisons with placebo and we don't know how shitty the women's diets were. Retrospective studies can be very misleading.
Appl Radiat Isot 1998 May-Jun;49(5-6):643-5
Body composition measurements using DXA and other techniques in tamoxifen-treated patients.
Ali PA, al-Ghorabie FH, Evans CJ, el-Sharkawi AM, Hancock DA.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9569566&dopt=Abstract
The conclusion of that study was:
"...this retrospective study indicates that tamoxifen may lead to increase in fat content in women who are subjected to this treatment. We conclude that this observation is probably related to the agonistic oestrogenic effect of Tamoxifen on body fat. To our knowledge this deleterious effect has not been reported before and it should be taken into consideration when comprising different types of anti-oestrogenic drugs. Furthermore, patients should be warned about this side-effect when they are prescribed Tamoxifen therapy."
Considering the potential for hyperlipidemia, the reduction in circulating IGF-1 levels, and the increase in body fat, it might not be the best strategy for fat loss.
All this is said with the proviso that this research was carried out in women, the women were probably taking the nolvadex longer than you intend to, and the research was retrospective. The latter is important because it means the conditions under which the women took the nolvadex were not controlled. There were no comparisons with placebo and we don't know how shitty the women's diets were. Retrospective studies can be very misleading.